Utilities | Company Research




2015年4月1日 增持 下调

Market Data: 03 Feb

Closing Price (HK\$)	12.98
Price Target (HK\$)	15.41
HSCEI	12,346
HSCCI	4,650
52-week High/Low (HK\$)	14.06/7.20
Market Cap (US\$m)	7,508
Market Cap (HK\$m)	58,199
Shares Outstanding (m)	4,484
Exchange Rate (Rmb-HK\$)	1.27

Price Performance Chart:



Hang Seng Chin

Source: Bloomberg

Analyst Daniel Huang A0230513030001 BDQ227

huangzhe@swsresearch.com Rong Ye A0230512110001 AYZ033

verong@swsresearch.com Dimi Du A0230514070005 BEE282

duwei@swsresearch.com

Related Reports

"Capacity for growth" Feb 04, 2015 "Pricing power enhanced " Nov 19,2014

The company does not hold any equities or derivatives of the listed company mentioned in this report ("target"), but then we shall provide financial advisory services subject to the relevant laws and regulations. Any affiliates of the company may hold equities of the target, which may exceed 1 percent of issued shares subject to the relevant laws and regulations. The company may also provide investment banking services to the target. The Company fulfills its duty of disclosure within its sphere of knowledge. The clients may contact compliance@swsresearch.com for relevant disclosure materials or log into www.swsresearch.com under disclosure column for further information. The clients shall have a comprehensive understanding of the disclosure and disclaimer upon the last page.



光大国际 (257:HK)

Financial summary and valuation

	2013	2014	2015E	2016E	2017E
Revenue (HK\$m)	5,319.87	6,355.12	10,217.00	12,063.92	14,056.08
YOY (%)	56.03	19.46	60.77	18.08	16.51
Net income (HK\$m)	1,364.20	1,765.04	2,539.76	3,269.45	3,885.58
YOY (%)	50.91	29.38	43.89	28.73	18.84
EPS (HK\$)	0.33	0.38	0.55	0.71	0.84
Diluted EPS (HK\$)	0.33	0.38	0.55	0.71	0.84
ROE (%)	9.90	10.47	14.00	16.59	18.05
Debt/asset (%)	41.29	42.81	42.92	45.94	48.77
Dividend yield (%)	0.65	0.73	1.06	1.36	1.62
PE (x)	39.82	34.17	23.62	18.35	15.44
PB (x)	3.83	3.26	3.00	2.74	2.50
EV/Ebitda (x)	26.11	21.73	16.31	13.55	11.66

Note: Diluted EPS is calculated as if all outstanding convertible securities, such as convertible preferred shares, convertible debentures, stock options and warrants, were exercised.

投资要点:

业绩低于预期。光大国际公布 14 年业绩,收入为 63.6 亿港币同比增长 19.5%, 利润 17.7 亿港币,同比增长 29.4%。每股收益为 0.38 港币同比增长 16.5%。业 绩小幅低于我们和市场的预期。

项目延期。总投资为 4.51 亿港币的 5 个垃圾发电项目延期,使得垃圾发电板块的建造收入仅仅为 32 亿港币,同比增长 25.8%。污水处理板块的建造收入为 1.12 亿港币,同比下降 75.1%。新能源板块建造收入为 3.5 亿港币,同比增长 132%。2014 年总建造收入为 36 亿元,同比仅增长 16.4%。

产能增长加速。公司 14 年共增加垃圾日处理产能 4900 吨,截止 14 年底公司垃圾日处理产能达到 14550 吨(同比增长 50.8%)。新项目获取加速,14 年公司新获垃圾日处理产能达到 13400 吨,相比 13 年的 3250 吨增长巨大。公司在建、筹建项目对应垃圾日处理产能达到 23850 吨。

利润率稳定。14 年公司 Ebitda 利润率小幅上升至 47%(13 年为 44%)。其中垃 圾发电 Ebitda 利润率上升 3 个百分点至 46%,污水处理 Ebitda 利润率上升 3 个 百分点至 54%,新能源 Ebitda 利润率上升 5 个百分点至 40%。产能利用率的提升 是导致公司利润率提升的主要原因。14 年公司垃圾发电产能利用率进一步上升 至 134%,同比提升 7 个百分点。污水处理产能利用里维持在 88%。

下调至增持。我们在模型中反映开工延期和产能利用率增长两项因素。建造放缓和效率提升将相互抵消其对收入和净利润的影响。我们维持 15-17 年每股收益 0.55/0.71/0.84 港币不变,每股收益同比增长分别为 37.9%/30.5%/19%。我们维持目标价 15.41,对应 15 年 21.3 倍 PE。鉴于目标价相对于现价 18.7%的涨幅,我们下调评级至增持。

Investment Highlights:

Results miss. China Everbright International reported 2014 revenue of HK\$6.36bn (+19.5% YoY) and net profit of HK\$1.77bn (+29.4% YoY). EPS came in at HK\$0.38 (+16.5%YoY). The results were slightly lower than both SWS and market expectations.

Project delay. The company reported delays to five waste to energy (WTE) projects in 2014, with total investment of HK\$451m. Construction revenue for the WTE segment rose 25.8% YoY to HK\$3.2bn for the year, construction revenue for waste water treatment (WWT) projects fell 75.1% YoY to HK\$112m, and construction revenue for alternative energy projects expanded 132% YoY to HK\$350m. Overall construction revenue was HK\$3.6 in 2014, up just 16.4% YoY.

Accelerated capacity additions. The company added new WTE capacity of 4,900t/day in 2014, bringing its total capacity in operation to 14,550t/d (+50.8% YoY). Including pipeline capacity acquisitions, the company secured 13,400t/d in 2014 additional capacity, vs additions of 3,250t/d in 2013, and bringing total pipeline capacity to 23,850t/d.

Stable margin. The company's Ebitda margin improved from 44% in 2013 to 47% in 2014, with Ebitda margin from WTE at 46% (+3ppts YoY), Ebitda margin from WWT at 54% (+3ppts YoY) and Ebitda margin for alternative energy projects at 40% (+5ppts YoY), as the company raised efficiency at its projects. The company achieved a 134% WTE utilisation rate, up 7ppts YoY, while WWT utilisation was flat at 88%.

Downgrade to Outperform. We update our model to factor in the slower-thanexpected pace of project construction and improving efficiency, finding that the two largely offset each other. We maintain our EPS forecasts of HK\$0.55 (+37.9% YoY) in 15E, HK\$0.71 (+30.5% YoY) in 16E and forecast HK\$0.84 (+19% YoY) for 17E. We maintain our target price at HK\$15.41, representing 21.3x 15E PE. Since our last report in early February, the company's stock has gained c.23%; our target price has 18.7% upside remaining, and we therefore downgrade our rating from BUY to Outperform.

APPENDIX

Consolidated Income Statement

HK\$ m	2013	2014	2015E	2016E	2017E
Revenue	5,320	6,355	10,217	12,064	14,056
Cost of sales	-2,944	-3,387	-6,046	-6,967	-8,060
Gross profit	2,375	2,969	4,171	5,097	5,996
Other income	144	219	204	241	492
Distribution expense	-0	32	52	61	71
Administrative expense	-392	-540	-638	-609	-739
Ebitda	2,348	2,863	4,171	5,097	5,996
Ebit	1,955	2,356	3,585	4,549	5,329
Finance costs	-316	-381	-403	-491	-634
Profit before taxation	1,812	2,299	3,386	4,359	5,187
Income tax	-447	-534	-847	-1,090	-1,297
Minority interests	40	62	76	98	117
Profit	1,364	1,765	2,540	3,269	3,886

Source: SWS Research

Consolidated Cash Flow Statement

HK\$ m	2013	2014	2015E	2016E	2017E
Profit before taxation	1,812	2,299	3,386	4,359	5,187
Depr. and amortisation	70	77	85	93	103
Finance cost	316	381	403	491	634
Losses from investments	0	0	0	0	0
Change in working capital	-2,424	-4,393	-4,255	-5,189	-6,179
Others	-138	46	46	46	46
CF from operating activities	-364	-1,590	-335	-200	-210
CAPEX	-56	-800	-800	-800	-800
Other CF from investing activities	-894	0	0	0	0
CF from investing activities	-950	-800	-800	-800	-800
Equity financing	3,617	0	0	0	0
Net change in liabilities	807	2,215	1,044	1,168	1,308
Dividend and interest paid	-263	-345	-426	-616	-793
Other CF from financing activities	-266	-381	-403	-491	-634
CF from financing activities	3,894	1,488	216	61	-119
Net cash flow	2,579	-902	-919	-939	-1,129
FCFF	43	(2,012)	(208)	126	295
FCFE	1,276	584	1,239	3,831	4,551

Source: SWS Research

HK\$ m	2013	2014	2015E	2016E	2017E
Current Assets	8,244	8,487	6,817	6,596	6,340
Bank balances and cash	5,814	5,150	2,836	1,940	937
Trade and other receivables	2,319	3,185	3,823	4,492	5,233
Inventories	76	117	123	129	136
Other current assets	35	35	35	35	35
Long-term investment	467	463	463	463	463
PP&E	1,374	1,511	1,662	1,828	2,011
Intangible and other assets	13,421	20,747	25,095	30,382	36,662
Total Assets	23,471	31,200	34,001	39,233	45,441
Current Liabilities	3,572	4,981	5,488	6,060	6,705
Borrowings	1,780	2,611	3,003	3,454	3,972
Trade and other payables	1,734	2,302	2,418	2,538	2,665
Other current liabilities	58	68	68	68	68
Long-term liabilities	6,121	8,360	9,104	11,964	15,457
Total Liabilities	9,692	13,357	14,592	18,024	22,161
Minority Interests	405	1,580	1,817	2,089	2,403
Shareholder Equity					
Share Capital	448	7,405	7,405	7,405	7,405
Reserves	12,926	8,858	10,187	11,714	13,472
Equity attributable	13,374	16,263	17,592	19,120	20,877
Total Liabilities and equity	23,471	31,200	34,001	39,233	45,441

Consolidated Balance Sheet

Source: SWS Research

1 April 2015

Key Fir	nancial	Ratios
----------------	---------	--------

	2013	2014	2015E	2016E	2017E
Ratios per share (HK\$)					
Earnings per share	0.33	0.38	0.55	0.71	0.84
Diluted EPS	0.33	0.38	0.55	0.71	0.84
Operating CF per share	-0.09	-0.35	-0.07	-0.04	-0.05
Dividend per share	0.09	0.09	0.14	0.18	0.21
Net assets per share	3.39	3.98	4.33	4.73	5.19
Key Operating Ratios(%)					
ROIC	22.3	23.0	20.6	21.2	20.9
ROE	9.9	10.5	14.0	16.6	18.1
Gross profit margin	44.7	46.7	40.8	42.2	42.7
EBITDA Margin	45.9	48.2	41.0	43.8	46.0
EBIT Margin	40.0	42.2	37.1	39.7	41.4
Growth rate of Revenue(YoY)	56.0	19.5	60.8	18.1	16.5
Growth rate of Profit(YoY)	50.9	29.4	43.9	28.7	18.8
Debt-to-asset ratio	41.3	42.8	42.9	45.9	48.8
Turnover rate of net assets	38.6	27.8	41.0	44.2	46.9
Turnover rate of total	0.0	0.0	0.0		0.0
assets	0.0	0.0	0.0	0.0	0.0
Effective tax rate (%)	36.9	50.4	24.8	24.8	24.0
Dividend yield (%)	0.7	0.7	1.1	1.4	1.6
Valuation Ratios (X)					
P/E	39.8	34.2	23.6	18.4	15.4
P/B	3.8	3.3	3.0	2.7	2.5
EV/Sale	12.0	10.5	6.7	5.9	5.4

Source: SWS Research



Information Disclosure :

The views expressed in this report accurately reflect the personal views of the analyst. The analyst declares that neither he/she nor his/her associate serves as an officer of nor has any financial interests in relation to the listed corporation reviewed by the analyst. None of the listed corporations reviewed or any third party has provided or agreed to provide any compensation or other benefits in connection with this report to any of the analyst, the Company or the group company(ies). A group company(ies) of the Company confirm that they, whether individually or as a group (i) are not involved in any market making activities for any of the listed corporation reviewed; or (ii) do not have any individual employed by or associated with any group company(ies) of the Company serving as an officer of any of the listed corporation reviewed; or (iii) do not have any financial interest in relation to the listed corporation reviewed or (iv) do not, presently or within the last 12 months, have any investment banking relationship with the listed corporation reviewed.

Undertakings of the Analyst

I (We) am (are) conferred the Professional Quality of Securities Investment Consulting Industry by the Securities Association of China and have registered as the Securities Analyst. I hereby issue this report independently and objectively with due diligence, professional and prudent research methods and only legitimate information is used in this report. I am also responsible for the content and opinions of this report. I have never been, am not, and will not be compensated directly or indirectly in any form for the specific recommendations or opinions herein.

Disclosure with respect to the Company

The company is a subsidiary of Shenwan Hongyuan Securities. The company is a qualified securities investment consulting institute approved by China Securities Regulatory Commission with the code number ZX0065.

Releasing securities research reports is the basic form of the securities investment consulting services. The company may analyze the values or market trends of securities and related products or other relevant affecting factors, provide investment analysis advice on securities valuation/ investment rating, etc. by issuing securities research reports solely to its clients.

The Company fulfills its duty of disclosure within its sphere of knowledge. The clients may contact <u>compliance@swsresearch.com</u> for the relevant disclosure materials or log into <u>www.swsresearch.com</u> for the analysts' qualifications, the arrangement of the quiet period and the affiliates' shareholdings.

Introduction of Share Investment Rating

Security Investment Rating :

When measuring the difference between the markup of the security and that of the market's benchmark within six months after the release of this report, we define the terms as follows:

Trading BUY: Share price performance is expected to generate more than 20% upside over a 6-month period.

BUY: Share price performance is expected to generate more than 20% upside over a 12-month period.

Outperform: Share price performance is expected to generate between 10-20% upside over a 12-month period.

Hold: Share price performance is expected to generate between 10% downside to 10% upside over a 12-month period.

Underperform: Share price performance is expected to generate between 10-20% downside over a 12-month period.

SELL: Share price performance is expected to generate more than 20% downside over a 12-month period.

Industry Investment Rating:

When measuring the difference between the markup of the industry index and that of the market's benchmark within six months after the release of the report, we define the terms as follows:

Overweight: Industry performs better than that of the whole market;

Equal weight: Industry performs about the same as that of the whole market;

Underweight : Industry performs worse than that of the whole market.

We would like to remind you that different security research institutions adopt different rating terminologies and rating standards. We adopt the relative rating method to recommend the relative weightings of investment. The clients' decisions to buy or sell securities shall be based on their actual situation, such as their portfolio structures and other necessary factors. The clients shall read through the whole report so as to obtain the complete opinions and information and shall not rely solely on the investment ratings to reach a conclusion. The Company employs its own industry classification system. The industry classification is available at our sales personnel if you are interested.

HSCEI is the benchmark employed in this report.

Disclaimer :

This report is to be used solely by the clients of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities, hereinafter referred to as the "Company"). The Company will not deem any other person as its client notwithstanding his receipt of this report.

This report is based on public information, however, the authenticity, accuracy or completeness of such information is not warranted by the Company. The materials, tools, opinions and speculations contained herein are for the clients' reference only, and are not to be regarded or deemed as an invitation for the sale or purchase of any security or other investment instruments.

The clients understand that the text message reminder and telephone recommendation are no more than a brief communication of the research opinions, which are subject to the complete report released on the Company's website (<u>http://www.swsresearch.com</u>). The clients may ask for follow-up explanations if they so wish.

The materials, opinions and estimates contained herein only reflect the judgment of the Company on the day this report is released. The prices, values and investment returns of the securities or investment instruments referred to herein may fluctuate. At different periods, the Company may release reports which are inconsistent with the materials, opinions and estimates contained herein.

Save and except as otherwise stipulated in this report, the contactor upon the first page of the report only acts as the liaison who shall not provide any consulting services.

The clients shall consider the Company's possible conflict of interests which may affect the objectivity of this report, and shall not base their investment decisions solely on this report. The clients should make investment decisions independently and solely at your own risk. Please be reminded that in any event, the company will not share gains or losses of any securities investment with the clients. Whether written or oral, any commitment to share gains or losses of securities investment is invalid. The investment and services referred to herein may not be suitable for certain clients and shall not constitute personal advice for individual clients. The Company does not ensure that this report fully takes into consideration of the particular investment objectives, financial situations or needs of individual clients. The Company strongly suggests the clients to consider themselves whether the opinions or suggestions herein are suitable for the clients' particular situations; and to consult an independent investment consultant if necessary.

Under no circumstances shall the information contained herein or the opinions expressed herein forms an investment recommendation to anyone. Under no circumstances shall the Company be held responsible for any loss caused by the use of any contents herein by anyone. Please be particularly cautious to the risks and exposures of the market via investment. 1 April 2015

Independent investment consultant should be consulted before any investment decision is rendered based on this report or at any request of explanation for this report where the receiver of this report is not a client of the Company.

The Company possesses all copyrights of this report which shall be treated as non-public information. The Company reserves all rights related to this report. Unless otherwise indicated in writing, all the copyrights of all the materials herein belong to the Company. In the absence of any prior authorization by the Company in writing, no part of this report shall be copied, photocopied, replicated or redistributed to any other person in any form by any means, or be used in any other ways which will infringe upon the copyrights of the Company. All the trademarks, service marks and marks used herein are trademarks, service marks or marks of the Company, and no one shall have the right to use them at any circumstances without the prior consent of the Company.

This report may be translated into different languages. The Company does not warrant that the translations are free from errors or discrepancies. This report is for distribution in Hong Kong only to persons who fall within the definition of professional investors whether under the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) (the "SFO") or the Securities and Futures (Professional Investor) Rules (Chapter 571D of the laws of the Hong Kong under the SFO).

This report is for distribution in the United Kingdom only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) order 2001 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc") of the Order (All such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons. Other Persons who are not Relevant Persons must not act or rely upon this document or any of its contents.

Disclaimer

This report was prepared, approved, published and distributed by the SWS Research Co., Ltd (subsidiary of Shenwan Hongyuan Securities) located outside of the United States (a "non-US Group Company"). This report is distributed in the U.S. by Enclave Capital LLC, a U.S. registered broker dealer, on behalf of SWS Research Co., Ltd only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through Enclave Capital LLC (19 West 44th Street, suite 1700, New York, NY 10036).

Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization.

The information has been compiled or arrived from sources believed to be reliable and in good faith, but no representation or warranty, express or implied is made as to their accuracy, completeness or correctness. SWS Research Co., Ltd has not verified the factual accuracy, assumptions, calculations or completeness of the information. Accordingly, SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) accepts no liability whatsoever for any direct or consequential loss or damage arising from (i) the use of this communication (ii) reliance of any information contained herein, (iii) any error, omission or inaccuracy in any such Information or (iv) any action resulting there from. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) provides the information for the purpose of the intended recipient's analysis and review. Accordingly you are advised to verify the factual accuracy, assumptions, calculations or completeness of the information.

Analyst Certification

Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report.

Important US Regulatory Disclosures on Subject Companies

This material was produced by SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. It is distributed in the United States of America by Enclave Capital LLC and elsewhere in the world by SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or an authorized affiliate of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities). This document does not constitute an offer of, or an invitation by or on behalf of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or company to subject or subjective judgments contained herein are made as of the date of this document. Emerging securities and other subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and wolumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.

1. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates have not recently been the beneficial owners of 1% or more of the securities mentioned in this report.

2. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates have not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.

3. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates have not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.

4. However, one or more person of SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon either on their own account or on behalf of their clients.

5. As of the publication of this report Enclave Capital LLC, does not make a market in the subject securities.

6. SWS Research Co., Ltd. (subsidiary of Shenwan Hongyuan Securities) or its Affiliates may, to the extent permitted by law, act upon or use the above material or the conclusions stated above or the research or analysis on which they are based before the material is published to recipients and from time to time provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report

Distribution in Singapore

If distributed in Singapore, this report is meant only for Accredited Investors and Institutional Investors as defined under Section 4A of the Securities and Futures Act of Singapore. If you are not an Accredited Investor or an Institutional Investor, you shall ignore the report and its contents. The Singapore recipients of the report are to contact the Singapore office of Shenyin Wanguo Singapore Private Limited at 65-6323-5208, or 65-6323-5209 in respect of any matters arising from, or in connection with, the report.